Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:53 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Longjohn Amgen Study - Effect of Denosumab...
NCT02444585 · University of Southern California · PHASE1 · withdrawn · last registry update 2020-11-10 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “No participants enrolled in the trial” | – | Registry record, University of Southern California |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TNFSF11 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-11-03Phase 3 first posted: Shenzhen People's Hospital, Denosumab + Zoledronic acid (NCT05106517)
- 2021-10-22Also stopped (terminated): Centre Leon Berard, denosumab (NCT03408652)
- 2021-10-21Phase 3 first posted: Gedeon Richter Plc., RGB-14-P + Prolia® (NCT05087030)
- 2021-10-07Results posted on the registry: M.D. Anderson Cancer Center, Ra-223 dichloride + Denosumab (NCT02366130)
- 2021-10-01Phase 3 first posted: Shenzhen People's Hospital, Denosumab Only Product (NCT05065164)
- 2021-09-28Also stopped (terminated): Amgen, Placebo + Denosumab (NCT01077154)
- 2021-09-27Phase 3 first posted: Shenzhen People's Hospital, Denosumab 60 mg/ml [Prolia] + Placebo (NCT05058443)
- 2021-08-31Results posted on the registry: University of Alabama at Birmingham, Denosumab (NCT02903446)
- 2021-06-22Phase 3 first posted: Fresenius Kabi SwissBioSim GmbH, FKS518 + US-licensed Prolia (Amgen) (NCT04934072)
- 2021-05-25Results posted on the registry: Peter Vestergaard, Cinacalcet 30 mg Tablet + Denosumab Inj 60 mg/ml (NCT03027557)
- 2021-05-11Results posted on the registry: Mishaela Rubin, Denosumab 60 mg/ml [Prolia] (NCT03457818)
- 2021-04-26Phase 3 first posted: Luye Pharma Group Ltd., LY01011 + Xgeva® (NCT04859569)
- 2021-04-21Results posted on the registry: Elizabeth Shane, Denosumab (NCT02049866)
- 2021-03-23Phase 3 first posted: Mabwell (Shanghai) Bioscience Co., Ltd., MW032 + Xgeva (NCT04812509)
- 2021-02-21Results posted on the registry: Children's Oncology Group, Denosumab (NCT02470091)
- 2021-02-17Phase 3 first posted: Celltrion, CT-P41 + US-licensed Prolia (NCT04757376)
- 2021-01-28Phase 3 first posted: Teva Pharmaceuticals USA, TVB-009 + Prolia® (NCT04729621)
- 2021-01-22Results posted on the registry: Massachusetts General Hospital, denosumab + teriparatide (NCT02176382)
- 2021-01-15Phase 3 first posted: Alliance for Clinical Trials in Oncology, Denosumab + Placebo (NCT04711109)
- 2021-01-14Results posted on the registry: Aarhus University Hospital, Zoledronic Acid (NCT03087851)
- 2021-01-06Also stopped (terminated): European Organisation for Research and Treatment of Cancer - EORTC, Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA] (NCT03620149)
- 2020-12-11Phase 3 first posted: Samsung Bioepis Co., Ltd., SB16 (Proposed Denosumab Biosimilar) + Prolia® (Denosumab) (NCT04664959)
- 2020-10-19Phase 3 first posted: Shanghai Biomabs Pharmaceutical Co., Ltd., CMAB807 Injection + Prolia® (NCT04591275)
- 2020-09-16Phase 3 first posted: Qilu Pharmaceutical Co., Ltd., QL1206 + Xgeva (NCT04550949)
- 2020-09-14Phase 3 first posted: Ole Lander Svendsen, Denosumab Injection (NCT04547348)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision